BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drugs for most aggressive cancers. Ongoing international clinical trials with the Company's lead product BGB324 is in patients with lung cancer and leukaemia. The Company is a world leader in understanding the central role of AXL kinase in driving immune evasion, drug resistance and metastasis, key traits of aggressive cancer and the cause of the majority of cancer-related deaths.

We are grateful for the continued vote of confidence and congratulate on the successful transaction!